Blood And Marrow Transplantation
7
1
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
Plerixafor for Stem Cell Mobilization in Normal Donors
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
Intravesical Cidofovir for Hemorrhagic Cystitis
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation